L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway

BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related death worldwide. The poor prognosis of this disease highlights the urgent need to develop more effective therapies. Activation of the STAT3 represents a potential drug target for pancreatic cancer therapy. Currently, clinica...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Manag Res
Egile Nagusiak: Bai, Encheng, Yang, Lehe, Xiang, Youqun, Hu, Wanle, Li, Caleb, Lin, Jiayuh, Dai, Xuanxuan, Liang, Guang, Jin, Rong, Zhao, Chengguang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5868586/
https://ncbi.nlm.nih.gov/pubmed/29606890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S159090
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak